EGFR and non-small cell lung carcinoma: In another study, NSCLC PDO models were used to study the targeted therapies trametinib and selumetinib (MEK inhibitors), afatinib (EGFR inhibitor), BKM120 (PI3K inhibitor) and BGJ398 (FGFR inhibitor) targeted therapies at 0.01–10 μM concentrations for 96 h.